

WE CAN RAPIDLY RULE OUT MI

WITH LABORATORY HIGH-SENSITIVTY TROPONIN ASSAYS

With ONE TEST on arrival...

Using cutoffs around the limit of detection

ALSO with ONE test on arrival...


Using decision aids like HEART, T-MACS, EDACS

With TWO TESTS 1-3


hours apart...

Using a validated algorithm


BUT THERE ARE STILL PROBLEMS...





BUT THERE ARE STILL PROBLEMS...



BUT THERE ARE STILL PROBLEMS...









THE SENSITIVITY OF POCT


with testing 3 hours after arrival



Palamalai et al. / Clinical Biochemistry 46 (2013) 1631-1635



CARDIAC TROPONIN ASSAYS



Contemporary assay (example)



10% CV 99th %


High-sensitivity troponin assay (example)





POC HS-TROPONIN ASSAYS

Values rounded to integers (ng/L) and provided for whole blood

Diagrams not to scale







ABBOTT I-STAT ININX

Early evaluation of a prototype assay




Pickering et al. JAMA Cardiol. 2018;3(11):1108-1112



354 PATIENTS

57 had AMI



THE AUC WAS 0.975

This compared to 0.970 for Abbott ARCHITECT hs-cTnl



100% SENSITIVITY

With a single test, cutoff 11ng/L 95% CI 93.7-100.0%

QUIDEL-ORTHO TRIAGETRUE HS-CTNI

Boeddinghaus et al, J Am Coll Cardiol. 2020; 75 (10) 1111-1124



APACE SUBSTUDY

- Analysed in plasma samples
- 1,261 patients with suspected NSTEMI

RULE-OUT WITH 1 TEST

Cut-off 3ng/L

- Sensitivity 100.0%
 (95% CI 98.0 100.0%)
- 45% of patients ruled out

RULE-OUT AT 1 HOUR

<5ng/L on arrival and
 delta <3ng/L</pre>

- Sensitivity 100.0%
 (95% CI 95.9 100.0%)
- Another 10% of patients ruled out

SIEMENS ATELLICA VILI

First published evaluation



1,089 patients who had troponin measured

91 had an adjudicated diagnosis of AMI

The assay could rule out 21% of patients

Cut-off 4ng/L

NPV was 99.6%

95% CI 98.8 - 100.3%

Sensitivity 98.9% (95% CI 97.1-100.6%)

CHALLENGES

EVIDENCE BASE

 We need more prospective clinical studies, in whole blood

COST


- POCT costs MORE
- How do we get and show the value?

TRAINING

 Busy staff need to see the benefit of POCT over lab testing


WE WILL NEED TO DISRUPT CARE PATHWAYS

to make POCT work



WE WILL NEED TO DISRUPT CARE PATHWAYS

to make POCT work





Patients seen on arrival by a senior clinician

POCT in Rapid Assessment Unit


The patient does not move until results have been reviewed

TRIAGE TO SDEC

POCT on arrival

Immediate risk stratification

Low risk patients go to SDEC; repeat POCT when indicated



HOW ABOUT TESTING IN AMBULANCES?

THE ACCESS STUDY

HEART score + POC
troponin **CAN NOT**rule out AMI

Sensitivity 87.0% (Samsung LabGeo)

Cooper et al, Ann Emerg Med 2021 Jun;77(6):575-588







ROCHE COBAS H232 CTNT HAD A SENSITIVITY OF 50.8% FOR TYPE 1 MI

95% CI 37.7 - 63.9%

THE HEART SCORE HAD A SENSITIVITY OF 86.4%



T-MACS HAD A SENSITIVITY OF 98.31.



Step 1

Assays become commercially available

Step 2

Analytical validation
(99th percentile, LoD, 10% CV)

Step 3


Evaluate
diagnostic
accuracy
(0/1h, 0/2h, 0/3h,
decision aids)

Step 4

Evaluate clinical/cost effectiveness of implementation


Step 5

Implementand evaluate
effectiveness




WE ARE HERE


IN SUMMARY



To date, point of care troponin tests have been unable to **rule out** acute MI



There are now several commercially available high-sensitivity troponin assays at the point of care



Prior to implementation, we need more evidence of diagnostic accuracy and cost-effectiveness, & we must define new care pathways